Health and Fitness Health and Fitness
Fri, June 11, 2010
Thu, June 10, 2010
Wed, June 9, 2010
Tue, June 8, 2010
[ Tue, Jun 08th 2010 ] - Market Wire
O.C. Beverages Products Arrive
Mon, June 7, 2010
Sun, June 6, 2010
Sat, June 5, 2010
Fri, June 4, 2010
Thu, June 3, 2010
Wed, June 2, 2010
Tue, June 1, 2010
[ Tue, Jun 01st 2010 ] - Market Wire
Covidien???????????????????
Mon, May 31, 2010
Sat, May 29, 2010
Fri, May 28, 2010
Thu, May 27, 2010
Wed, May 26, 2010

Sunesis to Present at Upcoming Investor Conferences


//health-fitness.news-articles.net/content/2010/ .. to-present-at-upcoming-investor-conferences.html
Published in Health and Fitness on Thursday, June 3rd 2010 at 4:40 GMT by Market Wire   Print publication without navigation


SOUTH SAN FRANCISCO, CA--(Marketwire - June 3, 2010) - Sunesis Pharmaceuticals, Inc. (NASDAQ: [ SNSS ]), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced that Daniel Swisher, Chief Executive Officer of Sunesis, will present at three upcoming conferences:

  • 9th Annual Needham Healthcare Conference
    Wednesday, June 9 at 10:40 a.m. EDT
    New York Palace Hotel, New York City

  • Jefferies 2010 Global Life Sciences Conference
    Thursday, June 10 at 8:00 a.m. EDT
    Grand Hyatt, New York City

  • ThinkEquity Mid Year Check-Up on Healthcare
    Wednesday, June 16 at 11:30 a.m. EDT
    The Princeton Club, New York City

A live webcast of the Jefferies presentation on June 10th will be available on the Sunesis website at [ http://ir.sunesis.com ]. A replay of that webcast will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks following the presentation.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis, please visit [ http://www.sunesis.com ].

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.


Publication Contributing Sources